Skip to main navigation

Investor Relations

Investor Overview
Stock Information
- Stock Quote & Chart
News & Events
- News Releases
- Events
SEC Filings
Corporate Governance
Investor Resources

News Releases

News Releases

03 Feb '20

Black Diamond Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

29 Jan '20

Black Diamond Therapeutics Announces Pricing of Initial Public Offering

05 Dec '19

Black Diamond Therapeutics Closes $85 Million Series C Financing

26 Sep '19

Black Diamond Therapeutics to Present Preclinical Data on its Lead Product Candidate BDTX-189 at the European Society for Medical Oncology 2019

19 Sep '19

Black Diamond Therapeutics Names Christopher Roberts, Ph.D., as Chief Scientific Officer

12 Sep '19

Black Diamond Therapeutics Appoints Thomas Leggett as Chief Financial Officer

29 May '19

Black Diamond Therapeutics Appoints Industry Veteran as Chief Operating Officer and General Counsel

29 Mar '19

Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting

10 Jan '19

Black Diamond Therapeutics Closes $85 Million Series B Financing

11 Dec '18

Versant Ventures Launches Black Diamond Therapeutics

Pagination

First page
Previous page
Page 1
Current page 2
Next page
Last page

Displaying 11 - 20 of 20

Investor Tools

Print Page
E-mail Alerts
RSS Feeds

Request E-mail Alerts

Footer Links

ABOUT US

TECHNOLOGY

PIPELINE

NEWS

CAREERS

CONTACT

© 2020 Black Diamond Therapeutics, Inc. All rights reserved.

Facebook
Twitter
LinkedIn
Google+